natgillin/translations-raw huggingface dataset:
You can usually continue to take other medicines whilst you are being treated with Pioglitazone Teva. 
Običajno lahko še naprej jemljete druga zdravila medtem ko se zdravite z zdravilom Pioglitazon Teva.
Following oral administration of radiolabelled pioglitazone to man, recovered label was mainly in faeces (55%) and a lesser amount in urine (45%). 
Izločanje Po peroralnem dajanju radioaktivno označenega pioglitazona človeku so označevalec zaznali predvsem v blatu (55 %) in manjšo količino v urinu (45 %).
When treating patients who have at least one risk factor for development of congestive heart failure (e.g. prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start with the lowest available dose and increase the dose gradually. 
Pri zdravljenju bolnikov, ki imajo vsaj en dejavnik tveganja za razvoj kongestivnega srčnega popuščanja (npr. predhodni miokardni infarkt ali simptomatska koronarna arterijska bolezen), bi moral zdravnik začeti zdravljenje z najnižjim možnim odmerkom in ga postopoma višati.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
- if you have liver disease. 
- če imate obolenje jeter.
Frequencies are defined as: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). 
ki so prejemali pioglitazon v dvojno slepih študijah, so našteti spodaj, in sicer po razredih organskih sistemov in absolutni pogostnosti, kot je priporočeno po MedDRA. Pogostnosti so določene kot: zelo pogosti (≥1/10) ; pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Pioglitazone Teva with food and drink 
Zdravilo Pioglitazon Teva skupaj s hrano in pijačo
When Pioglitazone Teva is taken in combination with other medicines used to treat diabetes (such as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether you need to take a smaller dose of your medicines. 
Če boste jemali zdravilo Pioglitazon Teva skupaj z drugimi zdravili za zdravljenje sladkorne bolezni (kot so insulin, klorpropamid, glibenklamid, gliklazid, tolbutamid), vam bo zdravnik povedal, ali morate jemati nižje odmerke teh zdravil.
These findings were observed across species at plasma concentrations ≤ 4 times the clinical exposure. 
Te ugotovitve so potrdila opažanja pri vseh vrstah pri plazemskih koncentracijah ≤ 4-kratne plazemske koncentracije pri klinični izpostavitvi.
Pharmacotherapeutic group: Drugs used in diabetes, blood glucose lowering drugs, excl. insulins; ATC code: A10BG03. 
Farmakoterapevtska skupina: Zdravila za zdravljenje diabetesa, antidiabetiki; oznaka ATC: A10BG03.
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12506 patients, 0.15%) than in control groups (7 cases from 10212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029). 
O primerih raka mehurja so pogosteje poročali v meta-analizi kontroliranih kliničnih preskušanjih s pioglitazonom (19 primerov od 12506 bolnikov, 0,15 %) kot v kontrolnih skupinah (7 primerov od 10212 bolnikov, 0,07 %) HR = 2,64 (95 % IZ 1,11-6,31, P = 0,029).
5 Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical trials. 
5 O edemih so poročali pri 6-9 % bolnikov, zdravljenih s pioglitazonom leto dni v kontroliranih kliničnih preskušanjih.
Symptoms are unusual shortness of breath or rapid increase in weight or localised swelling (oedema). 
Simptomi so nenavadno težko dihanje ali hitro povečanje telesne mase ali lokalne otekline (edemi).
It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice. 
Priporočljivo je, da imat pri sebi nekaj kock sladkorja, bonbone,
Pioglitazone treatment may be initiated at 15 mg or 30 mg once daily. 
Zdravljenje s pioglitazonom lahko začnemo s 15 mg ali 30 mg enkrat dnevno.
There are no adequate human data to determine the safety of pioglitazone during pregnancy. 
Za ugotavljanje varnosti pioglitazona med nosečnostjo ni zadostnih podatkov iz preskušanj pri človeku.
These effects were independent of pioglitazone's effects on glycaemia and were statistically significantly different to glibenclamide. 
Ti učinki niso bili odvisni od pioglitazonovih učinkov na glikemijo in so se statistično značilno razlikovali od glibenklamida.
Risk factors for bladder cancer should be assessed before initiating pioglitazone treatment (risks include age, smoking history, exposure to some occupational or chemotherapy agents e.g. cyclophosphamide or prior radiation treatment in the pelvic region). 
Dejavnike tveganja za rak mehurja je treba oceniti pred začetkom zdravljenja s pioglitazonom (tveganja vključujejo starost, kajenje v anamnezi, izpostavljenost nekaterim poklicnim dejavnikom ali kemoterapiji npr. ciklofosfamidu ali zdravljenje pred obsevanjem v predelu medenice).
After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups. 
Ko so izločili bolnike, ki so bili v času diagnoze rak mehurja preiskovanemu zdravilu izpostavljeni manj kot eno leto, so ugotovili 7 primerov (0,06 %) raka mehurja pri pioglitazonu in 2 primera (0,02 %) v kontrolnih skupinah.
Brampton Road, Hampden Park, Eastbourne, East Sussex - BN22 9AG United Kingdom 
Brampton Road, Hampden Park, Eastbourne East Sussex - BN22 9AG Velika Britanija
Your doctor may increase the dose to a maximum of 45 mg once a day. 
Zdravnik vam lahko poveča odmerek do največ 45 mg enkrat na dan.
This medicine does not require any special storage precautions. 
Za shranjevanje zdravila niso potrebna posebna navodila.
31-546, Krakow Poland 
Mogilska 80. 31-546, Krakow Poland
At two years, glycaemic control (defined as HbA1c < 8.0%) was sustained in 69% of patients treated with pioglitazone, compared with 50% of patients on gliclazide. 
Po dveh letih je nadzor glikemije (definiran kot HbA1c < 8,0 %) vztrajal pri 69 % bolnikov, zdravljenih s pioglitazonom, v primerjavi s 50 % bolnikov, ki so prejemali gliklazid.
See section 4.2 for information on paediatric use. 
Za informacije o pediatrični uporabi glejte poglavje 4.2.
Close monitoring of glycaemic control should be considered (see section 4.4). 
Pretehtati je potrebno skrbno spremljanje glikemičnega nadzora (glejte poglavje 4.4).
2 Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments. 
2 O motnjah vida so poročali predvsem zgodaj v poteku zdravljenja, povezane pa so s spremembami vrednosti glukoze v krvi zaradi začasnih sprememb turgidnosti in refrakcijskega indeksa leče, kot jih opažamo tudi pri zdravljenju z drugimi hipoglikemiki.
Before you start taking Pioglitazone Teva you will have a blood sample taken to check your liver function. 
Pred začetkom jemanja zdravila Pioglitazon Teva vam bodo odvzeli vzorec krvi, da se preveri delovanje vaših jeter.
Within each system organ class, adverse reactions are presented in order of decreasing incidence followed by decreasing seriousness. 
V vsaki skupini organskih sistemov so neželeni učinki navedeni po padajoči pogostnosti in padajoči resnosti.
What Pioglitazone Teva is and what it is used for 
Kaj je zdravilo Pioglitazon Teva in za kaj ga uporabljamo
This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree. 
Ta poteka predvsem prek citokromov P450 2C8, v manjši meri pa so lahko vpletene tudi druge izooblike.
If ALT levels are increased to 3 X upper limit of normal during pioglitazone therapy, liver enzyme levels should be reassessed as soon as possible. 
Če se med zdravljenjem s pioglitazonom ravni ALT zvišajo do 3-kratne zgornje meje normalnih vrednosti, je treba ravni jetrnih encimov čimprej ponovno kontrolirati.
OTHER (FOR CALENDARISED PACKS) 
DRUGI PODATKI (OKRAJŠAVE ZA DNI V TEDNU ZA KOLEDARSKA PAKIRANJA)
What you need to know before you take Pioglitazone Teva Do not take Pioglitazone Teva 
Kaj morate vedeti, preden boste vzeli zdravilo Pioglitazon Teva Ne jemljite zdravila Pioglitazon Teva
Patients receiving pioglitazone had a mean reduction in HbA1c of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group. 
Bolniki, ki so prejemali pioglitazon, so imeli povprečno znižan HbA1c za 0,45 % v primerjavi s tistimi, ki so nadaljevali zdravljenje samo z insulinom, in znižan odmerek insulina v skupini zdravljeni s pioglitazonom.
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Pioglitazone Teva. 
Obstaja povečana možnost zanositve, ker lahko spet pride do ovulacije, ko ste vzeli zdravilo Pioglitazon Teva.
The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator. 
Izračunana incidenca zlomov je bila 1,9 zlomov na 100 bolniških let pri ženskah, zdravljenih s pioglitazonom in 1,1 zlomov na 100 bolniških let pri ženskah, zdravljenih s primerjalnim zdravilom.
Following oral administration, pioglitazone is rapidly absorbed, and peak plasma concentrations of unchanged pioglitazone are usually achieved 2 hours after administration. 
Absorpcija Po peroralnem dajanju se pioglitazon hitro absorbira, maksimalne plazemske koncentracije nespremenjenega pioglitazona so običajno dosežene 2 uri po dajanju.
Österreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97 0070 
ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97 0070
Pioglitazone has been shown to be present in the milk of lactating rats. 
Pioglitazon so dokazali v mleku doječih podgan.
To be eligible patients had to have had one or more of the following: myocardial infarction, stroke, percutaneous cardiac intervention or coronary artery bypass graft, acute coronary syndrome, coronary artery disease, or peripheral arterial obstructive disease. 
Da bi bolniki ustrezali kriterijem, so morali imeti v anamnezi eno ali več od sledečega: miokardni infarkt, kap, perkutano srčno intervencijo ali koronarni arterijski transplantatni obvod, akutni koronarni sindrom, koronarno arterijsko bolezen ali periferno arterijsko obstrukcijsko bolezen.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics. 
Učinek pioglitazona (45 mg monoterapija v primerjavi s placebom) so preučevali v majhnem 18tedenskem preskušanju pri diabetikih tipa 2.
- The tablets are supplied in blisters in packs of 14, 28, 30, 50, 56, 84, 90, 98, 112 or 196 tablets. 
- Tablete so na voljo v pretisnih omotih v pakiranjih po 14, 28, 30, 50, 56, 84, 90, 98, 112 ali 196 tablet.
In one year clinical trials, pioglitazone consistently gave a statistically significant reduction in the albumin/creatinine ratio compared to baseline. 
V enoletnih kliničnih preskušanjih je pioglitazon vedno statistično značilno znižal razmerje albumin/kreatinin v primerjavi z izhodiščnimi vrednostmi.
No information is available from dialysed patients therefore pioglitazone should not be used in such patients. 
Podatkov o uporabi pioglitazona pri bolnikih na dializi ni, zato ga pri takih bolnikih ne smemo uporabljati.
In an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included insulin. 
V študiji izida bolnikov z že obstoječimi težjimi makrovaskularnimi boleznimi, je bila incidenca resnega srčnega popuščanja 1,6 % višja s pioglitazonom kot s placebom, dodanim k zdravljenju, ki je vključevalo insulin.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. 
Študije medsebojnih delovanj so pokazale, da pioglitazon nima pomembnega učinka na farmakokinetiko ali farmakodinamiko digoksina, varfarina, fenprokumona in metformina.
General disorders and administration site conditions oedema5 
Splošne težave in spremembe na mestu aplikacije edem5
• The risk of bladder cancer risk and relevant risk minimisation advice. 
• Tveganje za nastanek raka mehurja in ustrezen nasvet za zmanjšanje tveganja.
Fertility In animal fertility studies there was no effect on copulation, impregnation or fertility index. 
Plodnost V študijah plodnosti pri živalih ni bilo vpliva na parjenje, oploditev ali rodnost.
No dose adjustment is necessary for elderly patients (see section 5.2). 
Pri starejših bolnikih odmerka ni treba prilagajati (glejte poglavje 5.2).
Aluminium/aluminium blisters, packs of 14, 28, 30, 50, 56, 84, 90, 98, 112 and 196 tablets 
Aluminij/aluminij pretisni omoti, pakiranja po 14, 28, 30, 50, 56, 84, 90, 98, 112 in 196 tablet.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
• Redno posodobljena poročila o varnosti zdravila Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7)
common common uncommon macular oedema not known not known not known not known not known 
občasni makularni edem neznana neznana neznana neznana neznana
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with Pioglitazone Teva and insulin experienced the development of heart failure. 
Nekateri bolniki z dolgotrajno sladkorno boleznijo tipa 2 in srčno boleznijo ali predhodno kapjo, ki so bili zdravljeni z zdravilom Pioglitazon Teva in insulinom so doživeli razvoj srčnega popuščanja.
• The physician educational pack should contain: The Summary of Product Characteristics, package leaflet, and a Prescriber Guide. 
• Izobraževalno gradivo za zdravnike mora vsebovati: Povzetek glavnih značilnosti zdravila,
14 tablets 28 tablets 30 tablets 50 tablets 56 tablets 84 tablets 90 tablets 98 tablets 112 tablets 196 tablets 
14 tablet 28 tablet 30 tablet 50 tablet 56 tablet 84 tablet 90 tablet 98 tablet 112 tablet 196 tablet
The decision whether to continue the patient on therapy with pioglitazone should be guided by clinical judgement pending laboratory evaluations. 
Odločitev o tem, ali zdravljenje bolnika s pioglitazonom nadaljevati, naj do laboratorijskih vrednotenj temelji na klinični presoji.
In clinical trials with pioglitazone there was evidence of dose related weight gain, which may be due to fat accumulation and in some cases associated with fluid retention. 
V kliničnih preskušanjih s pioglitazonom so opažali pridobivanje telesne mase povezano z odmerkom, ki je lahko posledica nabiranja maščob in v nekaterih primerih povezano z zadrževanjem tekočine.
This is to check that your liver is working normally. 
To je potrebno zaradi nadzora normalnega delovanja vaših jeter.
- The other ingredients are mannitol, carmellose calcium, hydroxypropylcellulose and magnesium stearate. 
- Druge pomožne snovi so: manitol, hidroksipropilceluloza, kalcijev karmelozat in magnezijev stearat.
• Caution in use in the elderly in light of age related risks (in particular bladder cancer, fractures and heart failure) 
• Opozorilo o uporabi pri starejših glede na s starostjo povezana tveganja (zlasti za rak mehurja,
- Pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4.4). 
Pioglitazon je indiciran tudi za kombinacijo z insulinom pri odraslih bolnikih s sladkorno boleznijo tipa 2 z nezadostnim nadzorom glikemije, ki se zdravijo z insulinom, za katere je metformin, zaradi kontraindikacij ali neprenašanja, neprimeren (glejte poglavje 4.4).
There have been rare reports of hepatocellular dysfunction during post-marketing experience (see section 4.8). 
V postmarketinških izkušnjah so poročali o redkih primerih hepatocelularne disfunkcije (glejte poglavje 4.8).
as monotherapy 
kot monoterapija
very common (may affect more than 1 in 10 people) - decreased blood sugar (hypoglycaemia) 
zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov) - znižanje ravni krvnega sladkorja (hipoglikemija)
In this study in patients receiving pioglitazone and insulin, a higher percentage of patients with heart failure was observed in patients aged ≥65 years compared with those less than 65 years (9.7% compared to 4.0%). 
V tej študiji so pri bolnikih, ki so se zdravili s pioglitazonom in z insulinom, večji odstotek srčnega popuščanja opazili pri bolnikih, starih 65 let in starejših, v primerjavi z bolniki, mlajšimi od 65 let (9,7 % v primerjavi s 4,0 %).
What Pioglitazone Teva is and what it is used for What you need to know before you take Pioglitazone Teva How to take Pioglitazone Teva Possible side effects 
Kaj je zdravilo Pioglitazon Teva in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Pioglitazon Teva Kako jemati zdravilo Pioglitazon Teva
- if you have had diabetic ketoacidosis (a complication of diabetes causing rapid weight loss, 
- če ste imeli diabetično ketoacidozo (zaplet sladkorne bolezni, ki povzroča hitro hujšanje, slabost ali bruhanje).
3 In controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin. 
3 V kontroliranih kliničnih preskušanjih je bila incidenca poročil o srčnem popuščanju ob zdravljenju s pioglitazonom enaka kot v skupinah zdravljenja s placebom, metforminom in sulfonilsečnino, vendar je bila povečana pri uporabi kombiniranega zdravljenju z insulinom.
Patients should be observed for signs and symptoms of heart failure, weight gain or oedema; particularly those with reduced cardiac reserve. 
Bolnike je treba opazovati zaradi znakov in simptomov srčnega popuščanja, povečanja telesne mase ali edema, posebno tiste z zmanjšano srčno rezervo.
Environmental Risk Assessment (ERA): No environmental impact is anticipated from the clinical use of pioglitazone. 
Ocena tveganja za okolje: Pri klinični uporabi pioglitazona ni pričakovati vpliva na okolje.
Following initiation of therapy with pioglitazone, it is recommended that liver enzymes be monitored periodically based on clinical judgement. 
Po uvedbi zdravljenja s pioglitazonom je priporočeno, da jetrne encime spremljate redno po klinični presoji.
If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately. 
Če ste vzeli večji odmerek zdravila Pioglitazon Teva, kot bi smeli Če po nesreči zaužijete preveč tablet ali če kdo drug ali otrok zaužije vaša zdravila, nemudoma obvestite svojega zdravnika ali farmacevta.
Therefore, pioglitazone should not be administered to breast-feeding women. 
Zato se pioglitazona doječim ženskam ne sme dajati.
Since insulin and pioglitazone are both associated with fluid retention, concomitant administration may increase the risk of oedema. 
Ker sta insulin in pioglitazon povezana z zastajanjem tekočine, lahko sočasno jemanje poveča tveganje za edeme.
In the 3.5 year PROactive study, 44/870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%) of female patients treated with comparator. 
V 3,5 letni PROactive študiji, je 44/870 (5,1 %) žensk, zdravljenih s pioglitazonom imelo zlome, v primerjavi s 23/905 (2,5 %) žensk, zdravljenih s primerjalnim zdravilom.
It is not known whether pioglitazone is secreted in human milk. 
Ni znano, ali se pioglitazon izloča v materino mleko.
Pioglitazone should not be used in patients with hepatic impairment (see section 4.3 and 4.4). 
Jetrna okvara Pioglitazona pri bolnikih z jetrno okvaro ne smemo uporabljati (glejte poglavji 4.3 in 4.4).
Symptomatic and general supportive measures should be taken in case of overdose. 
V primerih prevelikega odmerjanja so potrebni splošni podporni ukrepi ter lajšanje simptomov.
Bladder cancer 
Rak mehurja
This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy thereby reducing the availability of metabolic substrates for foetal growth. 
To pripisujemo delovanju pioglitazona pri zniževanju materine hiperinsulinemije in povečani rezistenci na insulin, ki se pojavi med nosečnostjo, ter posledičnemu zmanjšanju razpoložljivosti presnovnih substratov za rast plodu.
Other medicines and Pioglitazone Teva 
Druga zdravila in zdravilo Pioglitazon Teva
Combination with metformin with sulphonylurea with metformin and sulphonylurea with insulin 
Kombinacija z metforminom s sulfonil sečnino z metforminom in sulfonil sečnino z inzulinom
Pioglitazone did not cause statistically significant increases in LDL cholesterol levels compared with placebo, whilst reductions were observed with metformin and gliclazide. 
Pioglitazon ni povzročil statistično značilnih povišanj ravni LDL holesterola v primerjavi s placebom, pri metforminu in gliklazidu pa so opazili znižanja teh vrednosti.
Co-administration of pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea. 
Ni videti, da bi sočasno dajanje pioglitazona s sulfonilsečninami vplivalo na farmakokinetiko sulfonilsečnine.
If you experience this symptom for the first time, talk to your doctor as soon as possible. 
Če ste prvič opazili ta simptom, se posvetujte s svojim zdravnikom kakor hitro mogoče.
Since there is a potential for an increase in doserelated adverse events, a decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. 
Ker obstaja možnost povečanja od odmerka odvisnih neželenih učinkov, bo morda ob sočasnem dajanju gemfibrozila potrebno znižati odmerek pioglitazona.
In combination with insulin, the current insulin dose can be continued upon initiation of pioglitazone therapy. 
V kombinaciji z insulinom lahko ob uvedbi zdravljenja s pioglitazonom nadaljujemo z dotedanjim odmerkom insulina.
In clinical studies, patients have taken pioglitazone at higher than the recommended highest dose of 45 mg daily. 
V kliničnih študijah so bolniki jemali pioglitazon v višjem od najvišjega priporočenega odmerka
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch. 
V natisnjenem navodilu za uporabo zdravila mora biti navedeno ime in naslov proizvajalca,
Pioglitazone dose adjustment within the recommended posology or changes in diabetic treatment should be considered (see section 4.5). 
Pretehtati je potrebno prilagoditev odmerka pioglitazona v okviru priporočenega odmerjanja ali spremeniti zdravljenje sladkorne bolezni (glejte poglavje 4.5).
Do not use this medicine after the expiry date which is stated on the carton and the blister after “EXP”. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in na pretisnem omotu, poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
If you are following a special diet for diabetes, you should continue with this while you are taking Pioglitazone Teva. 
Če ste na posebni dieti za sladkorno bolezen, jo med jemanjem zdravila Pioglitazon Teva nadaljujte.